Rx-360 Selects BSI Supply Chain Solutions to Lead Its International Joint Audit Program
Rx-360 announces a strategic partnership with BSI Supply Chain Solutions on Rx-360’s Joint Audit Program designed to enhance patient safety and increase supply chain security through on-the-ground supplier audits.
One of the world’s leading business solutions providers, BSI shares in Rx-360’s commitment to patient safety with its long history ensuring quality and consistency.
BSI will work with Rx-360 to further streamline the audit process and ensure supplier compliance with quality and security standards through verification audits. Overall security will be strengthened through improved supply chain transparency and visibility.
Rx-360, a not-for-profit international consortium representing the world’s leading pharmaceutical and biotech organizations, is committed to protecting patient safety. Recognizing that the globalization of suppliers has added significant complexity to ensuring supplier quality and security of the supply chain, Rx-360 has developed the Joint Audit program to verify and validate supplier compliance, enhance supply chain integrity and improve quality.
This innovative approach will allow multiple companies working with the same business partner to participate in a standardized audit without sacrificing product or process confidentiality. This in turn will significantly reduce audit costs, standardize the audit scope, expand the number of audits conducted, and ultimately reduce supplier audit fatigue while maintaining a high quality standard. The Joint Audit program will ensure audit consistency and transparency from audit scheduling through the required Corrective and Preventive Actions.
BSI was selected for this engagement following a thorough RFP process that considered more than a dozen other highly-qualified auditing firms. Rx-360 has chosen a partner in BSI that has proven its commitment to patient safety through its extensive work in the medical device industry.
With more than 70,000 clients worldwide and more than 150,000 audit days in 150 countries per year, BSI has the resources and infrastructure required to assist Rx-360 with their audit needs and is perfectly positioned to serve as a partner with Rx-360 members’ supplier base.
BSI will utilize its Supplier Verification (VerifEYE) services which will provide local personnel familiar with the local language, customs and traditions to conduct the audits. To ensure consistency of audits, these auditors will be trained by BSI Supply Chain Solutions to standards specific to Rx-360 members’ auditing requirements, including cGMP regulations as well as supply chain security.
Dan Purtell, Senior Vice President, Supply Chain Solutions stated: “By incorporating BSI’s extensive history of corporate auditing, our reputation in the medical device community for patient-safety, and our cutting-edge risk-based approach to supply chain security, we are able to offer Rx-360 a unique solution to meet their needs for efficient and comprehensive supplier auditing. This award will help Rx-360 members significantly reduce ineffective and overlapping audits while maintaining the overarching goal of increasing patient safety.”
Ben Mills, Co-Chair of Rx-360’s Audit Operations Group stated: “Rx-360’s primary mission is to ensure patient safety by maintaining high standards of quality during the manufacturing process. The Joint Audit program will allow consortium members to pool resources and have third-party audits conducted simultaneously while protecting commercially-sensitive and proprietary information. With BSI Supply Chain Solutions, Rx-360 has a partner known for experience, confidentiality, and quality. BSI’s risk-based approach to auditing will enhance effectiveness and supply chain security. The Joint Audit Program offers consortium members, suppliers and manufacturers alike, the opportunity to reduce the audit burden while amplifying product confidence and safety.”
BSI’s integration into Rx-360’s Joint Audit program will begin later this summer.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance